2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel fumarate - Relapsing Forms of Multiple Sclerosis | Phase 3 | Completed | Biogen | 136 | 2021-11-18 | 2025-10-24 |
| Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 4125 | 2010-09-13 | 2021-04-21 |
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1)
Fingolimod Hydrochloride (1) · diroximel fumarate (1)
Biogen (1) · Novartis Pharmaceuticals (1)
Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Egypt (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Greece (1)